Bristol-Myers Squibb’s Stock Performance: Analyzing Recent Gains and Future Prospects
Company Overview and Recent Market Performance
Bristol-Myers Squibb Company (BMY) stands out as a prominent biopharmaceutical firm specializing in treatments for cancer, immunologic, inflammatory, cardiovascular, and fibrotic diseases. The company’s market capitalization is an impressive $119.8 billion, with operations across various regions including the Americas, Europe, and the Indo-Pacific.
In the past year, Bristol-Myers has slightly underperformed the S&P 500 Index. Over the last 52 weeks, BMY’s stock has risen by 19.7%, while the S&P 500 has increased by 23.3%. However, in the year-to-date (YTD) metrics, BMY has outperformed, gaining 4.6% compared to the S&P 500’s 2.6% rise in 2025.
Comparison with Industry Peers
When zooming in on industry performance, Bristol-Myers has shown significant strength compared to the First Trust Nasdaq Pharmaceuticals ETF (FTXH), which has only gained 2.3% over the past year and 3.4% YTD.
Quarterly Results and Future Expectations
On October 31, following the release of its robust Q3 financial results, Bristol-Myers’ stock surged by 5.9%. Total revenues reached $11.9 billion, marking an 8.4% increase year-over-year and exceeding Wall Street expectations by more than 5%. However, adjusted net earnings fell by 11.8% to around $3.7 billion, though its adjusted earnings per share (EPS) stood at $1.80, which surpassed estimates by an impressive 20.8%.
Looking ahead, BMY is slated to report its fiscal 2024 results in the coming week. Analysts predict a notable decline in earnings, estimating a drop of 87.8% year-over-year to $0.92 per share. Notably, the company has a history of surpassing earnings expectations, achieving this in each of the last four quarters.
Analysts’ Ratings and Price Targets
Among 25 analysts covering Bristol-Myers stock, the consensus rating has shifted to “Moderate Buy.” This rating comprises seven “Strong Buy” recommendations, 17 “Hold” ratings, and one “Strong Sell.” This marks a transition from two months ago, where sentiment reflected a more cautious “Hold” rating with only six “Strong Buy” endorsements.
Truist Securities analyst Robyn Karnauskas recently reiterated a “Buy” rating, increasing the price target to $65, suggesting a potential upside of 9.9% from current prices. Meanwhile, BMY’s average price target sits at $60.09, providing a modest 1.6% upside, with the highest target of $73 indicating a substantial potential increase of 23.4%.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
